As a leading solution provider in ophthalmology, Ace Therapeutics is committed to providing comprehensive ophthalmology solutions to advance and support your project development. Here, we provide comprehensive and systematic ophthalmic drug preclinical research services. This will help you meet any challenges you may encounter at this significant stage of drug development.
Lack of preclinical ophthalmology models capable of simulating human ocular pathology.
Difficulty for drugs to penetrate the corneal barrier.
High sensitivity of ocular tissues to toxicity.
Ace Therapeutics has a professional research team to provide comprehensive drug discovery services for ocular diseases, including but not limited to small molecule ophthalmic drug discovery, gene therapy development, stem cell therapy development, and tissue-engineered cornea development.
We provide ophthalmology drug testing services to evaluate the efficacy of your drug candidates. Our customized in vivo ocular disease models and comprehensive ocular dosing services are designed to conduct in vivo ocular drug studies and evaluate your ophthalmic products.
Using biochemical and molecular techniques, we assist researchers in analyzing drug distribution in ocular cells and tissues, investigating drug mechanisms and pharmacological properties, and providing scientific support for drug development and optimization.
Our team of experts has experience in evaluating ocular histopathology studies, offering critical insights into the underlying causes of ocular diseases. The key areas of our ocular histopathology services include histopathological analysis, microscopy analysis, immunohistochemical analysis, molecular pathology analysis, and impression cytology analysis.
With extensive expertise in ophthalmology, we provide customized program development services to our clients. Our customized non-GLP ophthalmic program development services range from supporting clients with early pilot studies and proofs-of-concept to the implementation of preclinical GLP projects.
Ocular biospecimen analysis is a critical part of eye disease drug development. We provide ocular biospecimen services to assist our clients in elucidating ophthalmic disease mechanisms, identifying new ocular biomarkers, and evaluating potential therapies for eye diseases.
Specializing in ophthalmic biomarker development, we offer comprehensive solutions tailored to your research needs. Our expertise covers discovery, screening, identification, analysis, and translation of biomarkers, supporting decision-making and reducing project development risk.
"Their innovative use of continuous intraocular pressure telemetry in preclinical glaucoma studies uncovered circadian fluctuation patterns critical to our neuroprotection strategy, enabling data-driven candidate selection months ahead of schedule."
"Their hyperspectral imaging in preclinical retina drug testing captured microvascular dynamics we couldn’t visualize before, refining our lead candidate’s therapeutic window with unprecedented clarity. "
"Their multi-species retinal degeneration models in translational ophthalmic research pinpointed conserved inflammatory pathways, guiding our neuroprotective candidate optimization."
A group of optic neuropathy eye diseases that is characterized by progressive optic nerve degeneration and corresponding visual field loss.
LEARN MOREKnown as keratoconjunctivitis sicca, dry eye syndrome (DES), and dry eye, is a common chronic disease that affects many people worldwide.
LEARN MOREThe third leading cause of blindness worldwide, is the leading cause of vision loss in older adults.
LEARN MOREAn eye disease that is characterized by clouding of the lens, including congenital cataracts and age-related cataracts.
LEARN MOREOne of the common complications of diabetes that can lead to proliferative retinopathy, macular edema, and eventually blindness.
LEARN MOREVarious intraocular inflammatory diseases that occur in the uvea (iris, ciliary body, choroid) and its adjacent structures.
LEARN MOREThe separation of the neurosensory retina (NSR) from the underlying retinal pigment epithelium (RPE), is a vision-threatening condition.
LEARN MOREA phenomenon that occurs when the eye is unable to focus light from an object onto the plane of the retina, resulting in blurred images.
LEARN MOREKnown as pink eye, is an infection of the conjunctiva (the outermost eye layer covering the sclera).
LEARN MOREAce Therapeutics is your trusted partner in preclinical ophthalmic research, supporting your drug development projects.
CONTACT USYou can contact us any way that is convenient for you. We are available via email or our online contact form below. Please feel free to reach out with any questions or inquiries.
We would be happy to answer your questions.